
Opinion|Videos|March 24, 2025
Aligning Treatment Goals: Key Considerations for Patients and Caregivers in Late-Line RRMM
Author(s)Saad Usmani, MD, Amrita Krishnan, MD
Panelists discuss how quality of life priorities shift in late-line multiple myeloma treatment, with patients emphasizing the importance of maintaining independence in daily activities, preserving cognitive function, managing pain effectively, minimizing treatment-related side effects that impact social engagement, balancing treatment schedules to allow for meaningful family time and personal milestones and finding psychological peace through spirituality or support systems—ultimately revealing that while disease control remains critical, the ability to live with purpose and dignity increasingly shapes treatment decisions as patients progress through multiple therapy lines.
Advertisement
Video content above is prompted by the following:
- What quality of life factors are most important to you at this stage of your treatment journey?
Advertisement
Related to this article

The FDA flagged potential safety signals for colitis with Ibrance, Kisqali and Verzenio, and heart inflammation with melanoma drugs. No causal link is confirmed.

A biomarker test changed one mother’s diagnosis from suspected glioblastoma to ependymoma, but the report written in October did not reach her until December.

Anktiva is now approved for BCG-unresponsive papillary-only bladder cancer. Here’s what the bladder-sparing option involves, from timeline to risks.

The approval adds patients with high-grade papillary-only tumors, based on trial data showing a 62% complete response rate in patients with carcinoma in situ.

The 2026 cancer report found U.S. cancer death rates continued to fall from 2019 to 2023, largely due to lung cancer progress, while diagnoses rose slightly among women.

Patients with a newly identified tumor state had shorter survival following chemotherapy and immunotherapy, potentially helping doctors identify those at greater risk of poor outcomes.

Longer follow-up of the phase 2 LUNAR trial showed a 62% lower risk of progression, additional hormone therapy or death with 177Lu-PNT2002 plus radiation.
Advertisement
Advertisement
Trending on CURE
1
Radioligand Plus Radiation Delays Prostate Cancer Progression to 17.6 Months
2
FDA Expands Anktiva Approval in BCG-Unresponsive Bladder Cancer
3
What Is a Personalized Cancer Vaccine? What Patients Should Know
4
New Tumor Type May Help Identify High-Risk Small Cell Lung Cancer
5

